Jauregi Zinkunegi, A, Gleason, CE, Bendlin, B, Okonkwo, O, Hermann, BP, Blennow, K, Zetterberg, H, Hogervorst, E, Johnson, SC, Langhough, R, Mueller, KD and Bruno, D Menopausal hormone therapy is associated with worse levels of Alzheimer’s disease biomarkers in APOE4-carrying women: An observational study. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. ISSN 1552-5260 (Accepted)

Preview

Text MHT final.pdf - Accepted Version Download (956kB) | Preview

Abstract

INTRODUCTION: Menopausal hormone therapy (MHT), along with the apolipoprotein E (APOE) ε4 allele, has been suggested as a possible risk factor for Alzheimer’s disease (AD). However, the relationship between MHT and cerebrospinal fluid (CSF) biomarkers is unknown: we investigated this association, and whether APOE4 carrier status moderates it. METHODS: In an observational study of 134 cognitively unimpaired female participants (Mage=66.1; SD=6.3), we examined whether MHT use alone or in interaction with APOE4 carrier status was associated with CSF levels of ptau, Aβ40, Aβ42, p-tau/Aβ42 and Aβ42/40 ratios. RESULTS: Significant interactions were found between APOE4 and MHT use for CSF biomarkers. APOE4 carriers who were MHT users showed worse levels of CSF p-tau/Aβ42 and Aβ42/40 ratios, than all other users and non-users. DISCUSSION: The presence of both APOE4 and MHT may be associated with elevated amyloid deposition and AD pathology in this sample of participants who demonstrated high familial AD risk.

Item Type:	Article
Uncontrolled Keywords:	1103 Clinical Sciences; 1109 Neurosciences; Geriatrics
Subjects:	B Philosophy. Psychology. Religion > BF Psychology R Medicine > R Medicine (General) R Medicine > RG Gynecology and obstetrics
Divisions:	Psychology (from Sep 2019)
Publisher:	Wiley
SWORD Depositor:	A Symplectic
Date Deposited:	03 Dec 2024 14:39
Last Modified:	03 Dec 2024 14:39
URI:	https://researchonline.ljmu.ac.uk/id/eprint/24986

View Item